Bioventus Raises 2024 Guidance: Now Expects Net Sales Of $535M-$550M (Prior $520M-$535M) Vs. $528.033M Est., And Adj. EPS Of $0.25 To $0.33 (Prior $0.12-$0.20) Vs. $0.16 Est.

5/7/24 7:17:25 AM ET

Medical/Dental Instruments

Health Care

Get the next $BVS alert in real time by email

2024 Financial Guidance:

Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects:

Net sales of $535 million to $550 million—An increase of $15 million from previous guidance
Adjusted EBITDA* of $94 million to $99 million—An increase of $5 million from previous guidance
Non-GAAP EPS* of $0.25 to $0.33—An increase of $0.13 from previous guidance

Get the next $BVS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BVS

Date	Price Target	Rating	Analyst
12/7/2023	$7.00	Hold → Buy	Canaccord Genuity
8/9/2023	$4.00 → $6.00	Hold → Buy	Craig Hallum
11/22/2022		Buy → Hold	Craig Hallum
11/9/2022	$18.00 → $6.00	Buy → Hold	Canaccord Genuity
11/9/2022		Overweight → Underweight	JP Morgan
3/15/2022	$30.00	Buy	Craig Hallum
3/11/2022	$20.00 → $18.00	Overweight	Morgan Stanley
11/15/2021	$20.00	Overweight	Morgan Stanley

More analyst ratings

$BVS
Financials

Live finance-specific insights

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web
10/29/24 7:30:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs
7/30/24 7:30:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website
4/29/24 7:30:00 AM ET
$BVS
Medical/Dental Instruments
Health Care

$BVS
Market Insights

Live Market Insights

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. The company posted revenue of $1.058 billion, versus estimates of $974.361 million. Its earnings came in at 67 cents per share, versus expectations of 55 cents per share, according to data from Benzinga Pro. AppLovin shares jumped 14.8% to $85.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Pop Culture Group Co., Ltd (NASDAQ:CPOP) gained 60.3% to $2.71 in pre-market trading. Pop Culture reported revenue of $24 million for the six months ended Dec. 31, 2023, up from $12
5/9/24 8:13:28 AM ET
$AIXI
$APP
$ARGX
$BVS
Computer Software: Prepackaged Software
Technology
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading after the company reported mixed first-quarter financial results. Exact Sciences said first-quarter revenue increased 6% year-over-year to $638 million, which beat the consensus estimate of $627.355 million, according to Benzinga Pro. The company reported a quarterly loss of 60 cents per share, which missed analyst estimates for a loss of 48 cents per share. Exact Sciences shares dipped 17.4% to $49.15 in pre-market trading. Here are some big stocks recording losses in today's pre-mark
5/9/24 5:49:11 AM ET
$ABNB
$ARGX
$ARM
$BVS
Diversified Commercial Services
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8
Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $7 to $8.
5/8/24 12:35:00 PM ET
$BVS
Medical/Dental Instruments
Health Care

$BVS
Press Releases

Fastest customizable press release news feed in the world

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web
10/29/24 7:30:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Advanced Rehabilitation business of its subsidiary, Bioness, to Accelmed Partners ("Accelmed"), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction includes a total cash consideration of $45 million, including $25 million in cash at close (subject to a working capital adjustment) and up to $20 million in potential post-closing earn-out payments. At the time of closing, the Company expects to net approximatel
10/1/24 9:00:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioventus.com and will be available for replay on that site following the event. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and
8/7/24 4:15:00 PM ET
$BVS
Medical/Dental Instruments
Health Care

Apyx Medical Corporation Announces Board Leadership Transition
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
5/9/24 7:00:00 AM ET
$APYX
$BVS
$XTNT
Medical/Dental Instruments
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Bioventus Appoints Mark Singleton as Chief Financial Officer
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si
2/28/22 7:00:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus Appoints Michelle McMurry-Heath to Board of Directors
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex
12/21/21 9:25:00 AM ET
$BVS
Medical/Dental Instruments
Health Care

Bioventus Raises 2024 Guidance: Now Expects Net Sales Of $535M-$550M (Prior $520M-$535M) Vs. $528.033M Est., And Adj. EPS Of $0.25 To $0.33 (Prior $0.12-$0.20) Vs. $0.16 Est.

Chat with this insight

Recent Analyst Ratings for $BVS

$BVS Financials

Live finance-specific insights

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

$BVS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

$BVS SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Bioventus Inc.

SEC Form 10-Q filed by Bioventus Inc.

Bioventus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BVS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BVS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$BVS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

SVP & CFO Singleton Mark Leonard sold $51,350 worth of shares (9,219 units at $5.57), decreasing direct ownership by 10% to 84,895 units (SEC Form 4)

SVP & General Counsel D'Adamio Anthony sold $32,885 worth of shares (5,904 units at $5.57), decreasing direct ownership by 6% to 95,576 units (SEC Form 4)

Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

Bioventus upgraded by Canaccord Genuity with a new price target

Bioventus upgraded by Craig Hallum with a new price target

Bioventus downgraded by Craig Hallum

$BVS Market Insights

Live Market Insights

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8

$BVS Press Releases

Fastest customizable press release news feed in the world

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference

$BVS Leadership Updates

Live Leadership Updates

Apyx Medical Corporation Announces Board Leadership Transition

Bioventus Appoints Mark Singleton as Chief Financial Officer

Bioventus Appoints Michelle McMurry-Heath to Board of Directors

Recent Analyst Ratings for
$BVS

$BVS
Financials

$BVS
Insider Purchases

$BVS
SEC Filings

$BVS
Insider Trading

$BVS
Large Ownership Changes

$BVS
Analyst Ratings

$BVS
Market Insights

$BVS
Press Releases

$BVS
Leadership Updates